Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:AUGX Augmedix (AUGX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestTrends About Augmedix Stock (NASDAQ:AUGX) 30 days 90 days 365 days Advanced Chart Ad InvestorPlaceWall St. Icon: “If you wait on this, it will already be too late”If you have a significant amount of money in the stock market right now — or if you're sitting on the sidelines waiting to make a move — you DO NOT want to miss my latest research.Go here now to see my urgent warning Get Augmedix alerts:Sign Up Key Stats Today's Range$2.35▼$2.3550-Day Range$2.29▼$2.3552-Week Range$0.73▼$6.25VolumeN/AAverage Volume635,746 shsMarket Capitalization$115.07 millionP/E RatioN/ADividend YieldN/APrice Target$3.09Consensus RatingHold Company OverviewAugmedix, Inc. provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live that provides synchronous medical note documentation and point of care support; Augmedix Go Assist that offers asynchronous medical documentation based upon previously recorded visits; Augmedix Prep that provides patient demographics, past medical history, medication changes and other points from the patient's health record; and Augmedix Go, an autonomous, ambient AI mobile software application that offers fully automated medical documentation based upon recorded visits. The company enables clinicians to access its applications through mobile devices, such as smartphones. It serves health systems and specialty groups. The company was founded in 2013 and is headquartered in San Francisco, California.Read More… Augmedix Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks22nd Percentile Overall ScoreAUGX MarketRank™: Augmedix scored higher than 22% of companies evaluated by MarketBeat, and ranked 851st out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingAugmedix has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageAugmedix has received no research coverage in the past 90 days.Read more about Augmedix's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Augmedix is -5.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Augmedix is -5.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAugmedix has a P/B Ratio of 4.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for AUGX. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAugmedix does not currently pay a dividend.Dividend GrowthAugmedix does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for AUGX. News and Social Media0.6 / 5News SentimentN/A Search Interest1 people have searched for AUGX on MarketBeat in the last 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Augmedix insiders have not sold or bought any company stock.Percentage Held by Insiders10.97% of the stock of Augmedix is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions87.11% of the stock of Augmedix is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Augmedix's insider trading history. Receive AUGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Augmedix and its competitors with MarketBeat's FREE daily newsletter. Email Address AUGX Stock News HeadlinesCommure Completes Merger with AugmedixOctober 2, 2024 | globenewswire.com7 AI Penny Stocks to Watch in OctoberSeptember 27, 2024 | 247wallst.comCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.December 24, 2024 | Brownstone Research (Ad)STOCKHOLDER ALERT: The M&A Class Action Firm Investigates the Merger and Looming Vote on September 27, 2024, of Augmedix, Inc. - AUGXSeptember 6, 2024 | prnewswire.comAUGX Sep 2024 2.500 putAugust 18, 2024 | ca.finance.yahoo.comAUGX Sep 2024 2.500 callAugust 17, 2024 | ca.finance.yahoo.comAUGX Sep 2024 7.500 callAugust 17, 2024 | ca.finance.yahoo.comAUGX Stock Earnings: Augmedix Misses EPS, Misses Revenue for Q2 2024August 12, 2024 | investorplace.comSee More Headlines AUGX Stock Analysis - Frequently Asked Questions When did Augmedix IPO? Augmedix (AUGX) raised $40 million in an initial public offering (IPO) on Tuesday, October 26th 2021. The company issued 10,000,000 shares at $4.00 per share. William Blair, B. Riley Securities, Benchmark and Lake Street acted as the underwriters for the IPO. Who are Augmedix's major shareholders? Top institutional shareholders of Augmedix include Oddo BHF Asset Management Sas (4.95%), Trium Capital LLP (2.41%), HGC Investment Management Inc. (1.69%) and Geode Capital Management LLC (1.14%). Insiders that own company stock include Paul Ginocchio, Emmanuel Krakaris, Ian Shakil and Saurav Chatterjee. View institutional ownership trends. What other stocks do shareholders of Augmedix own? Based on aggregate information from My MarketBeat watchlists, some other companies that Augmedix investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Jabil (JBL), e.l.f. Beauty (ELF), Disc Medicine (IRON) and Novo Nordisk A/S (NVO). Company Calendar Today12/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Business services, not elsewhere classified Sub-IndustryBusiness Services Current SymbolNASDAQ:AUGX CUSIPN/A CIK1769804 Webwww.augmedix.com Phone888-669-4885FaxN/AEmployees1,430Year FoundedN/APrice Target and Rating Average Stock Price Target$3.09 High Stock Price Target$5.00 Low Stock Price Target$1.50 Potential Upside/Downside+31.4%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,170,000.00 Net Margins-46.23% Pretax Margin-46.10% Return on Equity-182.36% Return on Assets-43.21% Debt Debt-to-Equity Ratio1.48 Current Ratio1.66 Quick Ratio1.66 Sales & Book Value Annual Sales$51.58 million Price / Sales2.23 Cash FlowN/A Price / Cash FlowN/A Book Value$0.56 per share Price / Book4.20Miscellaneous Outstanding Shares48,968,000Free Float43,596,000Market Cap$115.07 million OptionableOptionable Beta-0.22 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report This page (NASDAQ:AUGX) was last updated on 12/24/2024 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredSix Stocks That Could Soar on Trump’s First Day BackThe recent election results have clarified a path forward, creating opportunities that weren't as clear just m...InvestorPlace | SponsoredTSLA *BANG* incoming (bullet in the chamber rn)I just pinpointed 5 dirt-cheap stocks that could soar the second the shot goes off. Thanks to Donald Trump’...StocksToTrade | SponsoredThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Augmedix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Augmedix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.